X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo: Good Show - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 27, 2001

    Glaxo: Good Show

    Glaxo India Ltd has posted a net profit of Rs 102 m (down 28%) for the quarter ended March 31, 2001. Net sales grew by 6.1% to Rs 1,944 m compared to Rs 1,832 m in the corresponding period last fiscal. Operating margins showed a significant improvement, increasing by more than 60 basis points. The dip in net profits was primarily due to comparatively lower other income. Other Income for the corresponding previous period last year included a income Rs 50 m from sale of brands. Barring Other Income, Profit Before Tax has in effect increased by more than 22.9%

    (Rs m) 1QFY01 1QFY02 Change
    Sales 1,832 1,944 6.1%
    Other Income 130 64 -50.8%
    Expenditure 1,689 1,781 5.4%
    Operating Profit (EBDIT) 143 163 14.0%
    Operating Profit Margin (%) 7.8% 8.4%  
    Interest 21 23 9.5%
    Depreciation 39 38 -2.6%
    Profit before Tax 213 166 -22.1%
    Other Adjustments      
    Tax 72 64 -11.1%
    Profit after Tax/(Loss) 141 102 -27.7%
    Net profit margin (%) 7.7% 5.2%  
    No. of Shares (eoy) (m) 60 60  
    Diluted Earnings per share* 9.4 6.8  
    P/E (at current price) 40.9 56.6  
    (*- annualised)      

    The company has also received approval of the shareholders to merge Smithkline Beecham Pharma with effect from 12th April 2001.

    In a related development the company recently decided to expand the business activities of its animal health division by entering new areas like antibiotic and ectoparasite and nutrition segments, launching technically superior products in cattle and poultry segment besides launching line extension of existing products.The animal healthmarket in the country is estimated to be around Rs 8 bn with the poultry sector alone contributing 45%.

    At the current market price of Rs 386, the stock is trading at 57 times its annualised 1QFY02 earnings.

     

     

    Equitymaster requests your view! Post a comment on "Glaxo: Good Show". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE GSK PHARMA WITH

    MARKET STATS